NasdaqGS:OSUR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has OraSure Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OSUR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: OSUR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

11.1%

OSUR

2.0%

US Medical Equipment

0.7%

US Market


1 Year Return

62.0%

OSUR

19.1%

US Medical Equipment

22.2%

US Market

Return vs Industry: OSUR exceeded the US Medical Equipment industry which returned 19.4% over the past year.

Return vs Market: OSUR exceeded the US Market which returned 22.7% over the past year.


Shareholder returns

OSURIndustryMarket
7 Day11.1%2.0%0.7%
30 Day-16.1%5.6%11.8%
90 Day16.4%6.3%8.6%
1 Year62.0%62.0%20.1%19.1%25.0%22.2%
3 Year-26.0%-26.0%75.3%70.8%49.4%39.5%
5 Year99.8%99.8%143.2%124.6%100.2%78.1%

Long-Term Price Volatility Vs. Market

How volatile is OraSure Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OraSure Technologies undervalued compared to its fair value and its price relative to the market?

16.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OSUR ($12.49) is trading below our estimate of fair value ($14.96)

Significantly Below Fair Value: OSUR is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: OSUR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: OSUR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OSUR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OSUR is good value based on its PB Ratio (2.3x) compared to the US Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is OraSure Technologies forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

102.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSUR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: OSUR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OSUR's is expected to become profitable in the next 3 years.

Revenue vs Market: OSUR's revenue (14.3% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: OSUR's revenue (14.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OSUR's Return on Equity is forecast to be low in 3 years time (5.2%).


Next Steps

Past Performance

How has OraSure Technologies performed over the past 5 years?

-8.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OSUR is currently unprofitable.

Growing Profit Margin: OSUR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OSUR is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare OSUR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSUR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).


Return on Equity

High ROE: OSUR has a negative Return on Equity (-3.7%), as it is currently unprofitable.


Next Steps

Financial Health

How is OraSure Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: OSUR's short term assets ($303.0M) exceed its short term liabilities ($37.2M).

Long Term Liabilities: OSUR's short term assets ($303.0M) exceed its long term liabilities ($11.3M).


Debt to Equity History and Analysis

Debt Level: OSUR is debt free.

Reducing Debt: OSUR has not had any debt for past 5 years.

Debt Coverage: OSUR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: OSUR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is OraSure Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OSUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OSUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSUR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OSUR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Steve Tang (59 yo)

2.67yrs

Tenure

US$2,114,821

Compensation

Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and Pre...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD2.11M) is about average for companies of similar size in the US market ($USD2.60M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Tang
President2.67yrsUS$2.11m0.28%
$ 2.5m
Roberto Cuca
CFO & Principal Accounting Officer2.5yrsUS$1.20m0.13%
$ 1.1m
Jack Jerrett
Senior VP20.08yrsUS$958.27k0.19%
$ 1.7m
Kathleen Weber
Executive VP & Business Unit Leader of Molecular Solutions8.08yrsUS$868.56k0.15%
$ 1.3m
Jeanne Mell
Vice President of Corporate Communications2.33yrsno datano data
Lisa Nibauer
Executive VP & Business Unit Leader of Infectious Disease0.58yrno data0.020%
$ 175.8k
Michele Miller
VP of Finance2.17yrsno data0.021%
$ 185.6k

2.5yrs

Average Tenure

53yo

Average Age

Experienced Management: OSUR's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stephen Tang
President2.67yrsUS$2.11m0.28%
$ 2.5m
David Shulkin
Independent Director0.67yrno data0.022%
$ 194.2k
Eamonn Hobbs
Independent Director4.75yrsUS$183.31k0.048%
$ 429.1k
Ronny Lancaster
Independent Director17.58yrsUS$185.00k0.033%
$ 297.6k
Michael Celano
Independent Chairman of the Board2.67yrsUS$220.00k0.093%
$ 836.1k
James Datin
Independent Director1.33yrsUS$124.98k0.024%
$ 215.9k
Mara Aspinall
Independent Director3.5yrsUS$170.00k0.037%
$ 334.3k
Lelio Marmora
Director0.50yrno data0.0098%
$ 87.6k

3.1yrs

Average Tenure

59.5yo

Average Age

Experienced Board: OSUR's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.


Top Shareholders

Company Information

OraSure Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OraSure Technologies, Inc.
  • Ticker: OSUR
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$895.942m
  • Shares outstanding: 71.73m
  • Website: https://www.orasure.com

Number of Employees


Location

  • OraSure Technologies, Inc.
  • 220 East First Street
  • Bethlehem
  • Pennsylvania
  • 18015
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OSURNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1986
EP3DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1986

Biography

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and inter...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/02 23:57
End of Day Share Price2020/12/02 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.